Company Dossier · Health Care
Edwards Lifesciences
- S&P 500
- Russell 1000
What Edwards Lifesciences is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $6.51 billion, up 14% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $1.43 billion, up 142% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.29 billion, up 38% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 31, 2025: $0.89 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (July 23, 2026): sentiment 0.60 on a −1 to +1 scale (mixed), confidence 0.80 of 1.Palanor Discourse
- Latest annual report (filed February 25, 2026): 3 risk factors added, 1 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $4.5 million on the open market.SEC Form 4
- 1,339 institutional managers reported a position at June 30, 2026 (+47 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 18 (34 a year earlier).U.S. Department of Labor (OFLC)
Risk events (12 months): 1 — latest OSHA inspection, May 21, 2026 →
Company Posture
How Company Posture is measured →What Edwards Lifesciences is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Steady · Mixed
Expanding ↔ Retrenching
Steady
- Capital spending94th pct
- Debt raised—
- Buybacks vs capex40th pct
- Hiring filings38th pct
- Deals and private raises49th pct
- Patent publications17th pct
Confident ↔ Hedging
Mixed
- Call sentiment40th pct
- Call confidence50th pct
- Guidance changes88th pct
- Risk factors added12th pct
- Insider open-market trades44th pct
- + Guidance changes
- − Risk factors added
- − Call sentiment
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver27th pct
- Stress filings48th pct
Credit
How these are built →Edwards Lifesciences's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$0.6B
- Due within a year $0.0B
- Longer term $0.6B
- Default point $0.3B (short + ½ long)
Finance leases included · Jun 30, 2026 filing
Bonds priced, last 12 months
None
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 20, 2026LobbyingLobbying report (AVENUE SOLUTIONS)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (BGR GOVERNMENT AFFAIRS)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (FARRAGUT PARTNERS LLP)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (AKIN GUMP STRAUSS HAUER & FELD)third_quarter 2026 · $0.1 million
- Oct 20, 2026LobbyingLobbying report (EDWARDS LIFESCIENCES, LLC)third_quarter 2026 · $0.3 million
- Oct 20, 2026Patent
- Oct 20, 2026Patent
- Oct 13, 2026PatentPatent granted: SENSOR STABILIZERUS 12758154
- Oct 6, 2026PatentPatent granted: TAPERED HEART VALVE COVERINGUS 12751822
- Oct 6, 2026Patent
- Aug 28, 20268-KDirector or officer changeItem 5.02
- Jul 20, 2026LobbyingLobbying report (EDWARDS LIFESCIENCES, LLC)second_quarter 2026 · $0.3 million
- Jul 20, 2026LobbyingLobbying report (BGR GOVERNMENT AFFAIRS)second_quarter 2026 · $0.1 million
- Jul 20, 2026LobbyingLobbying report (AVENUE SOLUTIONS)second_quarter 2026 · $0.1 million
- May 21, 2026Risk event
- May 8, 20268-KDirector or officer changeItem 5.02
- May 8, 20268-KShareholder vote resultsItem 5.07
- May 4, 20268-KDirector or officer changeItem 5.02
- Feb 25, 202610-KAnnual report (10-K)3 risk factors added, 1 removed
- Oct 30, 20258-KDirector or officer changeItem 5.02
- Jul 25, 20258-KDirector or officer changeItem 5.02
- May 8, 20258-KDirector or officer changeItem 5.02
- May 8, 20258-KShareholder vote resultsItem 5.07
- Feb 28, 202510-KAnnual report (10-K)2 risk factors added, 2 removed
- Feb 12, 202410-KAnnual report (10-K)2 risk factors added, 0 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Steris STE | $6.0B | $0.9B | Jun 30, 2026 |
| ResMed| RMD | $5.7B | $1.6B | Jun 30, 2026 |
| Zimmer Biomet ZBH | $8.5B | $1.5B | Jun 30, 2026 |
| Dexcom DXCM | $5.0B | $1.4B | Jun 30, 2026 |
| Idexx Laboratories IDXX | $4.5B | $1.3B | Jun 30, 2026 |
| Intuitive Surgical ISRG | $11.0B | $3.2B | Jun 30, 2026 |
| Baxter International BAX | $11.5B | — | Jun 30, 2026 |
| Bruker BRKR | $3.5B | $0.1B | Jun 30, 2026 |